SecBot SecBot
PRESS-RELEASE ·Filed Nov 2, 2026

CYTK

Cytokinetics, Incorporated
NEUTRAL
Impact 3/10
Horizondays Processed14d 14h ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

Monitor the November 6 presentations for any new efficacy or safety data on aficamten in nonobstructive HCM, which could influence the upcoming sNDA submission and eventual label expansion. The stock's normal daily move is 2.6%, so the event alone is unlikely to drive outsized volatility unless the data surprises materially.

DirectionNeutral
Confidencehigh
Horizondays

MYQORZO

▲ Bullish Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
Next catalyst
None dated

What to watchThe FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$62.03
T+0 close · Nov 2, 2026 · via day close
Latest settled
−11.11%
T+5 · $55.14 · next T+20 in 14d
Vs SPY
−11.19%
α at T+5
Latest observation
−10.57%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $62.03entry
  2. T+1 · 14d ago +0.45%α +0.15% · $62.31
  3. T+5 · 8d ago −11.11%α −11.19% · $55.14
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cytokinetics announced upcoming presentations of aficamten data at the HCM Medical Society Scientific Sessions, including two late-breaking oral abstracts from the ACACIA-HCM CMR study and a FOREST-HCM analysis. The company also reiterated its plan to submit a Supplemental New Drug Application for aficamten in nonobstructive HCM in Q4 2026, following positive Phase 3 topline results.

Key Facts

  • Cytokinetics will present two late-breaking oral abstracts and one poster on aficamten at the HCM Medical Society Scientific Sessions on November 6, 2026.
  • The ACACIA-HCM CMR study evaluates aficamten's effect on cardiac structure and function in nonobstructive hypertrophic cardiomyopathy.
  • The FOREST-HCM analysis examines left ventricular systolic dysfunction in long-term aficamten therapy for obstructive HCM.
  • Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in nonobstructive HCM in Q4 2026.
  • MYQORZO (aficamten) is already approved in the U.S., China, EU, UK, and Canada for symptomatic obstructive HCM.

Financial Impact

No financial figures disclosed; the event is a scientific presentation with no direct revenue or cost impact stated.

Risk Factors

  • Forward-looking statements regarding regulatory approval for aficamten in nHCM are subject to FDA and foreign agency decisions.
  • Competitive products or alternative therapies may be developed for hypertrophic cardiomyopathy.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3393043

Track record

46 reports on CYTK

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Viewing Entry $62.03 Now $53.17 −14.28% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (11h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026